

CORRECTION

Open Access



Correction: Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study

Shinya Kameda¹, Tomoko Fujii^{1*}, Junpei Ikeda², Akira Kageyama³, Toshishige Takagi¹, Naoki Miyayama¹, Kengo Asano¹, Arata Endo¹ and Shoichi Uezono⁴

Correction: BMC Nephrol (2023) 24:12
<https://doi.org/10.1186/s12882-023-03060-1>

Following publication of the original article [1], we have been informed that Figs. 1 and 2 were switched. Figure 1 should contain 8 components (a. pH to h. chloride) and Fig. 2 should be the curve.

The original article has been corrected.

Published online: 26 January 2023

Reference

1. Kameda S, et al. Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study. *BMC Nephrol.* 2023;24:12. <https://doi.org/10.1186/s12882-023-03060-1>.

The original article can be found online at <https://doi.org/10.1186/s12882-023-03060-1>.

*Correspondence:

Tomoko Fujii
tofujii-ky@umin.net

¹ Intensive Care Unit, The Jikei University Hospital, 3-19-18
Nishi-Shimbashi, Minato-Ku, Tokyo 105-8471, Japan

² Department of Clinical Engineering Technology, The Jikei University
Hospital, Tokyo, Japan

³ Department of Pharmacy, The Jikei University Hospital, Tokyo, Japan

⁴ Department of Anesthesiology, The Jikei University Hospital, Tokyo,
Japan



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.